Skip to Main Content

A Study of Balovaptan in Adults With Autism Spectrum Disorder With a 2-Year Open-Label Extension

Conditions

Mental Health & Behavioral Research

Phase III

What is the purpose of this trial?

Brief Summary:

This study will evaluate the efficacy, safety, and pharmacokinetics of 10 mg of oral administration balovaptan once a day (QD) compared with matching placebo in adults (18 years and older) with autism spectrum disorder (ASD).

  • Trial with
    Genentech, Inc.
  • Start Date
    03/26/2019
  • End Date
    12/30/2020
Trial Image

For more information about this study, contact:

Jane Jurayj

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8343

  • Last Updated
    09/18/2019
  • Study HIC
    #2000023946